Understanding the detailed molecular mechanisms by which CANA inhibits carcinogenesis, and generating clinical evidence to investigate whether SGLT2 inhibitors could prevent NASH-associated hepatocellular carcinoma in humans, require further studies. The gene discussed is SLC5A2; the disease is hepatocellular carcinoma.